Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Complementary therapies for inflammation

Article Abstract:

A study generates mice in which the native C5a receptor is replaced by its human counterpart and uses these animals to produce high-affinity monoclonal antibodies (mAbs) capable of preventing and reversing inflammation in a mouse model of rheumatoid arthritis. Antibodies against human C5aR generated using the knock-in strategy had IC50 values at least half those of the best in mAbs raised by a more conventional strategy involving use of C5aR-transferred cells as the immunogen.

Author: Yi Wang
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
United States, Care and treatment, Inflammation, Inflammation mediators

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Article Abstract:

Humanized monoclonal antibody directed against complement component C5, eculizumab, is developed and shown to block proinflammatory and cytolytic effects of terminal complement activation. Approval of eculizumab as a first-in-class complement inhibitor for treating hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH) validated the concept of complement inhibition as an effective therapy.

Author: Rollins, Scott A., Mojcik, Christopher F., Rother, Russell P., Bell, Leonard, Brodsky, Robert A.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Description and travel, Shortness of breath, Dyspnea, Blood diseases, Hematologic diseases

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Arming antibodies: Prospects and challenges for immunoconjugates

Article Abstract:

Immunoconjugates, monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs, are becoming a significant component of anticancer treatments. It is described that by combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic side effects than most conventional chemotherapeutic drugs.

Author: Wu, Anna M., Senter, Peter D.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Antibody-drug conjugates, Antineoplastic antibiotics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Monoclonal antibodies
Similar abstracts:
  • Abstracts: The impact of ethical sales behavior on customer satisfaction, trust and loyalty to the company: an emphirical study in the financial services industry
  • Abstracts: An empirical reconciliation of the Miller model and the generalized capital structure models. Are TIPS the "real" deal?: a conditional assessment of their role in a nominal portfolio
  • Abstracts: Has competition in the Japanese banking sector improved? Market structure and competitive conditions in the Arab GCC banking system
  • Abstracts: Agency costs and innovation: some empirical evidence. The impact of taxes on the choice of divestiture method
  • Abstracts: Comparison of prediction models for the compression force on the lumbosacral disc. Comparison of perceived comforts differences between standard and experimental load carriage systems
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.